Mereo BioPharma Group plc - Asset Resilience Ratio

Latest as of June 2020: 0.00%

Mereo BioPharma Group plc (MAH0) has an Asset Resilience Ratio of 0.00% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€0.00

≈ $0.00 USD Cash + Short-term Investments

Total Assets

€109.78 Million

≈ $128.35 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2019)

This chart shows how Mereo BioPharma Group plc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Mereo BioPharma Group plc to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Mereo BioPharma Group plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mereo BioPharma Group plc (MAH0) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€0.00	0%
Total Liquid Assets	€0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Mereo BioPharma Group plc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Mereo BioPharma Group plc Industry Peers by Asset Resilience Ratio

Compare Mereo BioPharma Group plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Mereo BioPharma Group plc (2017–2019)

The table below shows the annual Asset Resilience Ratio data for Mereo BioPharma Group plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2019-12-31	0.00%	€0.00 ≈ $0.00	€86.45 Million ≈ $101.07 Million	--
2018-12-31	3.72%	€2.50 Million ≈ $2.92 Million	€67.28 Million ≈ $78.65 Million	+1.12pp
2017-12-31	2.60%	€2.50 Million ≈ $2.92 Million	€96.34 Million ≈ $112.63 Million	--

pp = percentage points

About Mereo BioPharma Group plc

F:MAH0 Germany Biotechnology

Market Cap

$54.12 Million

€46.29 Million EUR

Market Cap Rank

#23504 Global

#2053 in Germany

Share Price

€0.29

Change (1 day)

+8.21%

52-Week Range

€0.20 - €1.96

All Time High

€4.48